ONYX-015 Enhances Radiation-Induced Death of Human Anaplastic Thyroid Carcinoma Cells

Journal of Clinical Endocrinology and Metabolism

Volumn 88, Issue 10, 2003, Pages 5027-5032

  Portella, Giuseppe ^a   Pacelli, Roberto ^a   Libertini, Silvana ^a   Cella, Laura ^a   Vecchio, Giancarlo ^a   Salvatore, Marco ^a   Fusco, Alfredo ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; DNA FRAGMENT; DOXORUBICIN; ONYX 015; PACLITAXEL;

ANAPLASTIC CARCINOMA; ANAPLASTIC THYROID CARCINOMA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER RADIOTHERAPY; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; CYTOTOXICITY; DRUG POTENTIATION; HUMAN; HUMAN CELL; LOW DRUG DOSE; NUDE MOUSE; PRIORITY JOURNAL; RADIATION DOSE; RADIOSENSITIVITY; THYROID CARCINOMA; TUMOR XENOGRAFT; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALS; CARCINOMA; CELL DEATH; COMBINED MODALITY THERAPY; DNA FRAGMENTATION; MICE; MICE, NUDE; RADIATION TOLERANCE; THYROID NEOPLASMS; TUMOR CELLS, CULTURED; VIRAL VACCINES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ADENOVIRIDAE; MUS MUSCULUS;

EID: 0242320345     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2003-030385     Document Type: Article

References (39)

1. Hedinger C, Williams ED, Sobin LH 1989 The WHO histological classification of thyroid tumours: a commentary on the second edition. Cancer 63:908-911
2. Wynford-Thomas D 1997 Origin and progression of thyroid epithelial tumours. Cellular and molecular mechanisms. Horm Res 47:145-157
3. Ain KB 1999 Anaplastic thyroid carcinoma: a therapeutic challenge. Semin Surg Oncol 16:64-69
4. Bischott J R, Kirn D H, Williams A, Heise C, Horn S, Muna M, Ng L, Nye JA, Sampson-Johannes A, Fattaey A, McCormick F 1996 An adenovirus mutant that replicates selectively in p53 deficient human tumor cells. Science 274:373-376
5. Ries SJ, Brandts CH, Chung A S, Biederer CH, Hann BC, Lipner EM, McCormick F, Korn WM 2000 Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant dl1520 (ONYX-015). Nat Med 6:1128-1133
6. Nemunaitis J, Ganly I, Khuri F, Arseneau J, Kuhn J, McCarty T, Landers S, Maples P, Romel L, Randlev B, Reid T, Kaye S, Kirn D 2000 Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. Cancer Res 15:6359-6366
7. Ito T, Seyama T, Mizuno T, Tsuyama N, Hayashi T, Hayashi Y, Dohi K, Nakamura N, Akiyama M 1992 Unique association of p53 mutations with undifferentiated but not differentiated carcinomas of the thyroid gland. Cancer Res 52:1369-1371
8. Fagin JA, Matsuo K, Karmakar A, Chen DL, Tang SH, Koeffler HP 1993 High prevalence of mutations of p53 gene in poorly differentiated human thyroid carcinomas. J Clin Invest 91:179-184
9. Dobashi Y, Sakamoto A, Sugimura H, Mernyei M, Mori M, Oyama T, Machinami R 1993 Overexpression of p53 as a possible prognostic factor in human thyroid carcinoma. Am J Surg Pathol 17:375-381
10. Donghi R, Longoni A, Pilotti S, Michieli P, Della Porta G, Pierotti MA 1993 p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. J Clin Invest 91:1753-1760
11. Matias-Guiu X, Cuatrecasas M, Musulen E, Prat J 1994 p53 expression in anaplastic carcinomas arising from thyroid papillary carcinomas. J Clin Pathol 47:337-339
12. Fusco A, Santoro M 1997 Human thyroid carcinogenesis. Forum 7.2:214-229
13. Khuri F R, Nemunaitis J, Ganly I, Arseneau J, Tannock IF, Romel L, Gore M, Ironside J, MacDougall RH, Heise C, Randlev B, Gillenwater AM, Bruso P, Kaye SB, Hong WK, Kirn DH 2000 A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer patients. Nat Med 6:879-885
14. Nemunaitis J, Khuri F, Ganly I, Arseneau J, Posner M, Vokes E, Kuhn J, McCarty T, Landers S, Blackburn A, Romel L, Randlev B, Kaye S, Kirn D 2001 Phase II trial of intratumoral administration of ONYX-015, a replicationselective adenovirus, in patients with refractory head and neck cancer. J Clin Oncol 19:289-298
15. Habib NA, Mitry RR, Sarraf CE, Habib NA, Mitry RR, Sarraf CE, Jiao LR, Havlik R, Nicholls J, Jensen SL 2002 Assessment of growth inhibition and morphological changes in in vitro and in vivo hepatocellular carcinoma models post treatment with dl1520 adenovirus. Cancer Gene Ther 9:414-420
16. Reid T, Galanis E, Abbruzzese J, Sze D, Wein LM, Andrews J, Randlev B, Heise C, Uprichard M, Hatfield M, Rome L, Rubin J, Kirn D 2002 Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints. Cancer Res 62:6070-6079
17. Reid T, Galanis E, Abbruzzese J, Sze D, Andrews J, Romel L, Hatfield M, Rubin J, Kirn D 2001 Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial. Gene Ther 21:1618-1626
18. Mulvihill S, Warren R, Venook A, Adler A, Randlev B, Heise C, Kirn D 2001 Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial. Gene Ther 8:308-315
19. Portella G, Scala S, Vitagliano D, Vecchio G, Fusco A 2002 ONYX-015, an E1B gene-defective adenovirus, induces cell death in human anaplastic thyroid carcinoma cell lines. J Clin Endocrinol Metab 87:2525-2531
20. Nemunaitis J, Cunningham C, Buchanan A, Blackburn A, Edelman G, Maples P, Netto G, Tong A, Randlev B, Olson S, Kirn D 2001 Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity. Gene Ther 8:746-759
21. Heise C, Sampson-Johannes A, Williams A, McCormick F, Von Hoff DD, Kirn DH 1997 ONYX-015, an aE1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med 3:639-545
22. You L, Yang C, Jablons DM 2000 ONYX-015 works synergistically with chemotherapy in lung cancer cell lines and primary cultures freshly made from lung cancer patients. Cancer Res 60:1009-1013
23. Pang X J, Hershman M, Chung M, Pekary AE 1989 Characterization of tumor necrosis factor-α receptors in human and rat thyroid cells and regulation of the receptors by thyrotropin. Endocrinology 125:1783-1788
24. Ain KB, Tofiq S, Taylor KD 1996 Antineoplastic activity of taxol against human anaplastic thyroid carcinoma cell lines in vitro and in vivo. J Clin Endocrinol Metab 81:3650-3653
25. Rogulski KR, Freytag SO, Zhang K Gilbert JD, Paielli DL, Kim JH, Heise CC, Kirn DH 2000 In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy. Cancer Res 60:1193-1196
26. Haigh PI 2000 Anaplastic thyroid carcinoma. Curr Treat Options Oncol 1:353-357
27. Yeung SJ, Xu G, Pan J, Christgen M, Bamiagis A 2000 Manumycin enhances the cytotoxix effect of paclitaxel on anaplastic thyroid carcinoma cells. Cancer Res 60:650-656
28. Xu G., Pan J, Martin C, Yeung SJ 2001 Angiogenesis inhibition in the in vivo antineoplastic effect of manumycin and paclitaxel against anaplastic thyroid carcinoma. J Clin Endocrinol Metab 86:1769-1777
29. Scala S, Portella G, Fedele M, Chiappetta G, Fusco A 2000 Adenovirus-mediated suppression of HMGI (Y) protein synthesis as potential therapy of human malignant neoplasias. Proc Nat Acad Sci USA 97:4256-4261
30. Lowe SW, Ruley HE, Jacks T, Housman DE 1993 p53-Dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74:957-967
31. Shao R, Karunagaran D, Zhou BPLi K, Lo SS, Deng J, Chiao P, Hung MC 1997 Inhibition of nuclear factor-KB activity is involved in E1A-mediated sensitization of radiation-induced apoptosis. J Biol Chem 272:32739-32742
32. Zhou Z, Jia S F, Hung MC, Kleinerman ES 2001 E1A sensitizes HER2/neu overexpressing Ewing's sarcoma cells to topoisomerase II-targeting anticancer drugs. Cancer Res 61:3394-3398
33. Frisch S, Mymryk J 2002 Adenovirus-5 E1A: paradox and paradigm. Nat Rev Mol Cell Biol 6:441-452
34. Deng J, Xia W, Hung MC 1998 Adenovirus 5 E1A-mediated tumor suppression associated with E1A-mediated apoptosis in vivo. Oncogene 17:2167-2175
35. Debbas M, White E 1993 Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B. Genes Dev 7:546-554
36. Putzer BM, Stiewe T, Parssanedjad K, Rega S, Esche H 2000 E1A is sufficient by itself to induce apoptosis independent of p53 and other adenoviral gene products. Cell Death Differ 7:177-188
37. Rothmann T, Hengstermann A, Whitaker NJ, Scheffner M, Zur Hausen H 1998 Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells. J Virol 72:9470-9478
38. Goodrum FD, Ornelles DA 1998 p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lyric infection. J Virol 72:9479-9490
39. Wadler S, Yu B, Tan JY, Kaleya R, Rozenblit A, Makower D, Edelman M, Lane M, Hyjek E, Horwitz M 2003 Persistent replication of the modified chimeric adenovirus ONYX-015 in both tumor and stromal cells from a patient with gall bladder carcinoma implants. Clin Cancer Res 9:33-43